Skip to main content

Advertisement

Log in

Scleroderma Mimics

  • SCLERODERMA (J VARGA, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Scleroderma is a rare systemic autoimmune disease with multiple organ manifestations, including skin fibrosis. The groups of disorders classified as scleroderma mimics share the common thread of skin thickening but are otherwise quite incongruous in terms of underlying disease process and other organ involvement. This article reviews the clinical presentation, etiology, and treatment options available for scleroderma mimics, including morphea, scleredema, diabetic cheiroarthropathy, scleromyxedema, nephrogenic systemic fibrosis, and eosinophilic fasciitis. Through greater understanding of these diseases and the associated extradermal implications, we hope to facilitate recognition of scleroderma and its mimics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. • Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011; 64(2):217–28. This is an excellent review of the spectrum of morphea and localized scleroderma.

  2. Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2005.

  3. • Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011; 64(2):231–42. This is an important summary on the direction in which outcome measures and treatment of localized scleroderma are moving.

  4. • Wortsman X, Gutierrez M, Saavedra T, Honeyman J. The role of ultrasound in rheumatic skin and nail lesions: a multi-specialist approach. Clin Rheumatol 2011; 30(6):739–48. This is a discussion of the use of ultrasound in evaluation of scleroderma skin.

  5. Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol. 2009;160(5):1075–82.

    Article  PubMed  CAS  Google Scholar 

  6. • Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2011; 63(7):1998–2006. This is an excellent example of how a randomized controlled trial can be carried out in this rare disease.

    Google Scholar 

  7. Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006;54(3):440–7.

    Article  PubMed  Google Scholar 

  8. Kreuter A, Hyun J, Skrygan M, Sommer A, Tomi NS, Breuckmann F, et al. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma. Arch Dermatol Res. 2006;298(6):265–72.

    Article  PubMed  CAS  Google Scholar 

  9. Kreuter A, Hyun J, Skrygan M, Sommer A, Bastian A, Altmeyer P, et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol. 2006;155(3):600–7.

    Article  PubMed  CAS  Google Scholar 

  10. Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum. 2006;35(6):355–9.

    Article  PubMed  Google Scholar 

  11. Dziadzio M, Anastassiades CP, Hawkins PN, Potter M, Gabrielli A, Brough GM, et al. From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. Clin Rheumatol. 2006;25(1):3–15.

    Article  PubMed  Google Scholar 

  12. Meguerditchian C, Jacquet P, Beliard S, Benderitter T, Valero R, Carsuzza F, et al. Scleredema adultorum of Buschke: an under recognized skin complication of diabetes. Diabetes Metab. 2006;32(5 Pt 1):481–4.

    Article  PubMed  CAS  Google Scholar 

  13. Ikeda Y, Suehiro T, Abe T, Yoshida T, Shinoki T, Tahara K, et al. Severe diabetic scleredema with extension to the extremities and effective treatment using prostaglandin E1. Intern Med. 1998;37(10):861–4.

    Article  PubMed  CAS  Google Scholar 

  14. Thumpimukvatana N, Wongpraparut C, Lim HW. Scleredema diabeticorum successfully treated with ultraviolet A1 phototherapy. J Dermatol. 2010;37(12):1036–9.

    Article  PubMed  Google Scholar 

  15. Alsaeedi SH, Lee P. Treatment of scleredema diabeticorum with tamoxifen. J Rheumatol. 2010;37(12):2636–7.

    Article  PubMed  Google Scholar 

  16. Rosenbloom AL. Limitation of finger joint mobility in diabetes mellitus. J Diabet Complications. 1989;3(2):77–87.

    Article  PubMed  CAS  Google Scholar 

  17. Rosenbloom AL. Diabetic thick skin and stiff joints. Diabetologia. 1989;32(1):74–6.

    Article  PubMed  CAS  Google Scholar 

  18. Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87(1):10–20.

    Article  Google Scholar 

  19. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol. 2003;42(1):31–5.

    Article  PubMed  Google Scholar 

  20. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44(2):273–81.

    Article  PubMed  CAS  Google Scholar 

  21. Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33(1):37–43.

    Article  PubMed  CAS  Google Scholar 

  22. Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, et al. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood. 2006;107(2):463–6.

    Article  PubMed  CAS  Google Scholar 

  23. Laimer M, Namberger K, Massone C, Koller J, Emberger M, Pleyer L, et al. Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema. Acta Derm Venereol. 2009;89(6):631–5.

    Article  PubMed  CAS  Google Scholar 

  24. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000–1.

    Article  PubMed  CAS  Google Scholar 

  25. • Morcos SK, Haylor J. Pathophysiology of nephrogenic systemic fibrosis: a review of experimental data. World J Radiol 2010; 2(11):427–33. This is an important summary of the relationship of gadolinium to NSF.

  26. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment—report of 33 cases. Radiology. 2009;250(2):371–7.

    Article  PubMed  Google Scholar 

  27. Schieren G, Wirtz N, Altmeyer P, Rump LC, Weiner SM, Kreuter A. Nephrogenic systemic fibrosis—a rapidly progressive disabling disease with limited therapeutic options. J Am Acad Dermatol. 2009;61(5):868–74.

    Article  PubMed  Google Scholar 

  28. Marckmann P, Skov L. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am. 2009;47(5):833–40. vi.

    Article  PubMed  Google Scholar 

  29. Kreuter A, Gambichler T, Weiner SM, Schieren G. Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis. Arch Dermatol. 2008;144(11):1527–9.

    Article  PubMed  Google Scholar 

  30. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58(8):2543–8.

    Article  PubMed  CAS  Google Scholar 

  31. Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant. 2011;26(3):1099–101.

    Article  PubMed  Google Scholar 

  32. Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians. 1975;88:70–86.

    PubMed  CAS  Google Scholar 

  33. Antic M, Lautenschlager S, Itin PH. Eosinophilic fasciitis 30 years after—what do we really know? Report of 11 patients and review of the literature. Dermatology. 2006;213(2):93–101.

    Article  PubMed  Google Scholar 

  34. Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol. 2008;47(1):29–35.

    Article  PubMed  Google Scholar 

  35. Fujimoto M, Sato S, Ihn H, Kikuchi K, Yamada N, Takehara K. Serum aldolase level is a useful indicator of disease activity in eosinophilic fasciitis. J Rheumatol. 1995;22(3):563–5.

    PubMed  CAS  Google Scholar 

  36. Baumann F, Bruhlmann P, Andreisek G, Michel BA, Marincek B, Weishaupt D. MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. AJR Am J Roentgenol. 2005;184(1):169–74.

    PubMed  Google Scholar 

  37. Barnes L, Rodnan GP, Medsger TA. Short D. Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol. 1979;96(2):493–518.

    PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Virginia Steen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nashel, J., Steen, V. Scleroderma Mimics. Curr Rheumatol Rep 14, 39–46 (2012). https://doi.org/10.1007/s11926-011-0220-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0220-8

Keywords

Navigation